IgA antibodies for cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 69-77

  Dechant, Michael ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fc RI; IgA; Immunotherapy; Neutrophils; Oncology

Indexed keywords

CD89 ANTIGEN; COMPLEMENT; DIMER; FC RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN RECEPTOR; ISOPROTEIN; MONOMER; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN A ANTIBODY; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER IMMUNOTHERAPY; CARCINOMA; CONFERENCE PAPER; HALF LIFE TIME; HUMAN; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; DIMERIZATION; HUMANS; IMMUNOGLOBULIN A; NEOPLASMS; PHARMACOKINETICS;

EID: 0034980163     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00105-6     Document Type: Conference Paper

References (64)

1. Monoclonal antibody therapy of cancer
2. Monoclonal antibody therapies - a 'constant' threat to cancer
3. Signaling antibodies in cancer therapy
4. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
5. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
6. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
7. Human antibodies by design
8. The structure and function of human IgA
9. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface
10. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling
11. The joining (J) chain is present in invertebrates that do not express immunoglobulins
12. Transepithelial transport of immunoglobulins
13. Lack of association of secretory component with IgA in J chain-deficient mice
14. Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab′)2: a possible implication for mucosal defense
15. Dimeric recombinant IgA directed against carcino-embryonic antigen, a novel tool for carcinoma localization
16. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments
17. Human chimeric IgA antibodies mediate improved effector cell recruitment against B-cell lymphoma
18. In vitro comparsion of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells
19. Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin
20. Recombinant human IgA expressed in insect cells
21. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans
22. FcRn: the MHC class I- related receptor that is more than an IgG transporter
23. Divergent roles for Fc receptors and complement in vivo
24. Structure and function of human IgA Fc receptors (FcαR)
25. Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils
26. Immunoglobulin-binding sites of human FcγRI (CD89) and bovine Fcα2R are located in their membrane-distal extracellular domains
27. Crosslinking of the human Fc receptor for IgA (FcαRI/CD89) triggers FcRγ-chain-dependent shedding of solubel CD89
28. Human immunoglobulin A receptor (FcαRI, CD89) function in transgenic mice requires both FcRγ-chain and CR3 (CD11b/CD18)
29. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcRγ-chain. Molecular basis for CD89/FcRγ-chain association
30. γ-Chain-dependent recruitment of tyrosine kinases to membrane rafts by the human IgA receptor FcαR
31. Role of Src in the modulation of multiple adaptor proteins in FcαRI oxidant signaling
32. Identification of residues in the first domain of human Fcα receptor essential for interaction with IgA
33. Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human Fcα-receptor (FcαR) CD89
34. Differential effects of the T helper cell type 2- derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils
35. A critical role for PI 3-kinase in cytokine-induced Fcα receptor activation
36. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
37. Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA
38. The asialoglycoprotein receptor: relationships between structure, function, and expression
39. The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit
40. Intracellular neutralization of virus by immunoglobulin A antibodies
41. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA
42. Killing of Steptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes
43. Addition of a μ-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4
44. Homodimerization of tumorreactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
45. Effective phagocytosis and killing of Candida albicans via targeting FcγRI (CD64) or FcαRI (CD89) on neutrophils
46. The human Fc receptor for IgA (FcαRI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis
47. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
48. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy
49. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies
50. Bispecific antibodies in cancer therapy
51. Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood
52. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
53. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells
54. Granulocytes as possible effectors of tumor immunity
55. Cytokines, tumour-cell death and immunogenicity: a question of choice
56. Secretory immunoglobulin A: from mucosal protection to vaccine development
57. FcαRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity
58. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants
59. Phase I trial of murine immunoglobulin A antitransferrin receptor antibody 42/6
60. Fcα/μ receptor mediates endocytosis of IgM-coated microbes